CVKD SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of Orphan Thrombo-Inflammatory Therapeutics

Oct 7, 2026

8-K

Cadrenal Therapeutics, Inc. Reports Voting Results from its 2026 Annual Meeting of Stockholders

Sep 29, 2026

8-K

Cadrenal Therapeutics Announces Positive FDA Feedback on Phase 3 Study Design for CAD-1005

Aug 31, 2026

8-K

Cadrenal Therapeutics, Inc. Reports Financial Results for the Quarter Ended June 30, 2026

Aug 13, 2026

8-K

Cadrenal Therapeutics Launches Partnering Process for Cardiac Acute Critical Care Assets

Jul 21, 2026

8-K

Cadrenal Therapeutics Announces Departure of Chief Medical Officer

Jul 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 20, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 1,180,003 | Bank: H.C. Wainwright & Co., LLC

Apr 29, 2026

424B5

SHARE RESALE REGISTRATION | Shares: 590,001

Apr 1, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 428,227 | Warrants amount: 428,227

Jan 2, 2026

424B5

December 2025 ATM | Offering amount: $1,770,028 | Amount sold to date: $7,111,714 | Float: 1,885,120

Dec 23, 2025

424B5

REGISTERED OFFERING

Dec 16, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 8, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 3, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Jul 15, 2026

S-3

SHARE RESALE REGISTRATION

Jul 13, 2026

S-3

SHARE RESALE REGISTRATION

Apr 20, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Apr 6, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Aug 3, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jul 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 31, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 31, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 12, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Pham Quang X (Reporting)

Oct 13, 2026

Golden Lee Scott (Reporting)

Oct 13, 2026

MURPHY JOHN RAYMOND (Reporting)

Oct 13, 2026

Cole Jeffrey Scott (Reporting)

Oct 13, 2026

WILSON GLYNN (Reporting)

Oct 13, 2026

SCHEDULE 13G

PNC FINANCIAL SERVICES GROUP, INC. (Filed by)

Aug 7, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 21, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 30, 2026

CORRESP

Form CORRESP - Correspondence

Apr 27, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 27, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 2, 2026

LETTER

Form UPLOAD - SEC-generated letter

Dec 31, 2025

Cadrenal Therapeutics, Inc. Common Stock CVKD · SEC Filings